Current use of antithymoglobulin as induction regimen in kidney transplantation: A review
Currently, various immunosuppressive drugs are used in organ transplantation. In particular, antithymoglobulin is a widely used drug in kidney transplantation in Korea, accounting for 20% of all induction therapy. According to existing studies, antithymoglobulin induction therapy has several advanta...
Gespeichert in:
| Veröffentlicht in: | Medicine (Baltimore) 2024-03, Vol.103 (9), p.e37242-e37242 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e37242 |
|---|---|
| container_issue | 9 |
| container_start_page | e37242 |
| container_title | Medicine (Baltimore) |
| container_volume | 103 |
| creator | Park, Byung Hwa Kim, Ye Na Shin, Ho Sik Jung, Yeonsoon Rim, Hark |
| description | Currently, various immunosuppressive drugs are used in organ transplantation. In particular, antithymoglobulin is a widely used drug in kidney transplantation in Korea, accounting for 20% of all induction therapy. According to existing studies, antithymoglobulin induction therapy has several advantages and disadvantages compared with other immunotherapies depending on the kidney transplant situation (dead donor, living donor, low-risk recipient, and high-risk recipient) or antithymoglobulin dose. In this review, we summarize the research conducted so far on antithymoglobulin and hope that antithymoglobulin research on kidney transplantation will be actively conducted in the future. |
| doi_str_mv | 10.1097/MD.0000000000037242 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2934270642</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2934270642</sourcerecordid><originalsourceid>FETCH-LOGICAL-c300t-720c3f9c2bf58304393a8ce25c8e4a1ea364607b69acb8adc10279b2f7e6889a3</originalsourceid><addsrcrecordid>eNpdkE1PwzAMhiMEYmPwC5BQjlw60iRtEm7Txpe0iQscOFVp6o5Am46kBfXf02kDJHyxZD2vbT0IncdkGhMlrlaLKfkrJiinB2gcJyyNEpXyQzQmhCaRUIKP0EkIb4TEW-oYjZjkVEouxuhl3nkPrsVdANyUWLvWtq993ayrJu8q67AO2LqiM61tHPawtjW4YYLfbeGgx63XLmyqIae3xDWeDdCnha9TdFTqKsDZvk_Q8-3N0_w-Wj7ePcxny8gwQtpIUGJYqQzNy0QywpliWhqgiZHAdQyapTwlIk-VNrnUhYkJFSqnpYBUSqXZBF3u9m5889FBaLPaBgPV8BI0XcioYpwKknI6oGyHGt-E4KHMNt7W2vdZTLKt02y1yP47HVIX-wNdXkPxm_mRyL4B2hdybw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2934270642</pqid></control><display><type>article</type><title>Current use of antithymoglobulin as induction regimen in kidney transplantation: A review</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Wolters Kluwer Open Health</source><source>IngentaConnect Free/Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Park, Byung Hwa ; Kim, Ye Na ; Shin, Ho Sik ; Jung, Yeonsoon ; Rim, Hark</creator><creatorcontrib>Park, Byung Hwa ; Kim, Ye Na ; Shin, Ho Sik ; Jung, Yeonsoon ; Rim, Hark</creatorcontrib><description>Currently, various immunosuppressive drugs are used in organ transplantation. In particular, antithymoglobulin is a widely used drug in kidney transplantation in Korea, accounting for 20% of all induction therapy. According to existing studies, antithymoglobulin induction therapy has several advantages and disadvantages compared with other immunotherapies depending on the kidney transplant situation (dead donor, living donor, low-risk recipient, and high-risk recipient) or antithymoglobulin dose. In this review, we summarize the research conducted so far on antithymoglobulin and hope that antithymoglobulin research on kidney transplantation will be actively conducted in the future.</description><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000037242</identifier><identifier>PMID: 38428847</identifier><language>eng</language><publisher>United States</publisher><subject>Antilymphocyte Serum - therapeutic use ; Clinical Protocols ; Graft Rejection - prevention & control ; Graft Survival ; Humans ; Immunosuppressive Agents - therapeutic use ; Kidney Transplantation ; Living Donors</subject><ispartof>Medicine (Baltimore), 2024-03, Vol.103 (9), p.e37242-e37242</ispartof><rights>Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c300t-720c3f9c2bf58304393a8ce25c8e4a1ea364607b69acb8adc10279b2f7e6889a3</cites><orcidid>0000-0002-3973-4541</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,861,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38428847$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Park, Byung Hwa</creatorcontrib><creatorcontrib>Kim, Ye Na</creatorcontrib><creatorcontrib>Shin, Ho Sik</creatorcontrib><creatorcontrib>Jung, Yeonsoon</creatorcontrib><creatorcontrib>Rim, Hark</creatorcontrib><title>Current use of antithymoglobulin as induction regimen in kidney transplantation: A review</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description>Currently, various immunosuppressive drugs are used in organ transplantation. In particular, antithymoglobulin is a widely used drug in kidney transplantation in Korea, accounting for 20% of all induction therapy. According to existing studies, antithymoglobulin induction therapy has several advantages and disadvantages compared with other immunotherapies depending on the kidney transplant situation (dead donor, living donor, low-risk recipient, and high-risk recipient) or antithymoglobulin dose. In this review, we summarize the research conducted so far on antithymoglobulin and hope that antithymoglobulin research on kidney transplantation will be actively conducted in the future.</description><subject>Antilymphocyte Serum - therapeutic use</subject><subject>Clinical Protocols</subject><subject>Graft Rejection - prevention & control</subject><subject>Graft Survival</subject><subject>Humans</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Kidney Transplantation</subject><subject>Living Donors</subject><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkE1PwzAMhiMEYmPwC5BQjlw60iRtEm7Txpe0iQscOFVp6o5Am46kBfXf02kDJHyxZD2vbT0IncdkGhMlrlaLKfkrJiinB2gcJyyNEpXyQzQmhCaRUIKP0EkIb4TEW-oYjZjkVEouxuhl3nkPrsVdANyUWLvWtq993ayrJu8q67AO2LqiM61tHPawtjW4YYLfbeGgx63XLmyqIae3xDWeDdCnha9TdFTqKsDZvk_Q8-3N0_w-Wj7ePcxny8gwQtpIUGJYqQzNy0QywpliWhqgiZHAdQyapTwlIk-VNrnUhYkJFSqnpYBUSqXZBF3u9m5889FBaLPaBgPV8BI0XcioYpwKknI6oGyHGt-E4KHMNt7W2vdZTLKt02y1yP47HVIX-wNdXkPxm_mRyL4B2hdybw</recordid><startdate>20240301</startdate><enddate>20240301</enddate><creator>Park, Byung Hwa</creator><creator>Kim, Ye Na</creator><creator>Shin, Ho Sik</creator><creator>Jung, Yeonsoon</creator><creator>Rim, Hark</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3973-4541</orcidid></search><sort><creationdate>20240301</creationdate><title>Current use of antithymoglobulin as induction regimen in kidney transplantation: A review</title><author>Park, Byung Hwa ; Kim, Ye Na ; Shin, Ho Sik ; Jung, Yeonsoon ; Rim, Hark</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c300t-720c3f9c2bf58304393a8ce25c8e4a1ea364607b69acb8adc10279b2f7e6889a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antilymphocyte Serum - therapeutic use</topic><topic>Clinical Protocols</topic><topic>Graft Rejection - prevention & control</topic><topic>Graft Survival</topic><topic>Humans</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Kidney Transplantation</topic><topic>Living Donors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Park, Byung Hwa</creatorcontrib><creatorcontrib>Kim, Ye Na</creatorcontrib><creatorcontrib>Shin, Ho Sik</creatorcontrib><creatorcontrib>Jung, Yeonsoon</creatorcontrib><creatorcontrib>Rim, Hark</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Park, Byung Hwa</au><au>Kim, Ye Na</au><au>Shin, Ho Sik</au><au>Jung, Yeonsoon</au><au>Rim, Hark</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Current use of antithymoglobulin as induction regimen in kidney transplantation: A review</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2024-03-01</date><risdate>2024</risdate><volume>103</volume><issue>9</issue><spage>e37242</spage><epage>e37242</epage><pages>e37242-e37242</pages><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract>Currently, various immunosuppressive drugs are used in organ transplantation. In particular, antithymoglobulin is a widely used drug in kidney transplantation in Korea, accounting for 20% of all induction therapy. According to existing studies, antithymoglobulin induction therapy has several advantages and disadvantages compared with other immunotherapies depending on the kidney transplant situation (dead donor, living donor, low-risk recipient, and high-risk recipient) or antithymoglobulin dose. In this review, we summarize the research conducted so far on antithymoglobulin and hope that antithymoglobulin research on kidney transplantation will be actively conducted in the future.</abstract><cop>United States</cop><pmid>38428847</pmid><doi>10.1097/MD.0000000000037242</doi><orcidid>https://orcid.org/0000-0002-3973-4541</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0025-7974 |
| ispartof | Medicine (Baltimore), 2024-03, Vol.103 (9), p.e37242-e37242 |
| issn | 0025-7974 1536-5964 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2934270642 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Wolters Kluwer Open Health; IngentaConnect Free/Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Antilymphocyte Serum - therapeutic use Clinical Protocols Graft Rejection - prevention & control Graft Survival Humans Immunosuppressive Agents - therapeutic use Kidney Transplantation Living Donors |
| title | Current use of antithymoglobulin as induction regimen in kidney transplantation: A review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T13%3A23%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Current%20use%20of%20antithymoglobulin%20as%20induction%20regimen%20in%20kidney%20transplantation:%20A%20review&rft.jtitle=Medicine%20(Baltimore)&rft.au=Park,%20Byung%20Hwa&rft.date=2024-03-01&rft.volume=103&rft.issue=9&rft.spage=e37242&rft.epage=e37242&rft.pages=e37242-e37242&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000037242&rft_dat=%3Cproquest_cross%3E2934270642%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2934270642&rft_id=info:pmid/38428847&rfr_iscdi=true |